CR20110219A - Ácidos naftilacéticos - Google Patents

Ácidos naftilacéticos

Info

Publication number
CR20110219A
CR20110219A CR20110219A CR20110219A CR20110219A CR 20110219 A CR20110219 A CR 20110219A CR 20110219 A CR20110219 A CR 20110219A CR 20110219 A CR20110219 A CR 20110219A CR 20110219 A CR20110219 A CR 20110219A
Authority
CR
Costa Rica
Prior art keywords
naphylactic
acids
esters
compounds
formula
Prior art date
Application number
CR20110219A
Other languages
English (en)
Inventor
Li Chen
Fariborz Firooznia
Paul Gillespie
Yun He
Tai-An Lin
Eric Mertz
Sung-Sau So
Hongying Yun
Zhenshan Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20110219A publication Critical patent/CR20110219A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/16Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a compuestos de la fórmula I, y a sales y ésteres farmacéuticamente aceptables de los mismos, en el que W, X, Y y R1-R7 tienen los significados definidos en la descripción detallada y en las reivindica-ciones.
CR20110219A 2008-11-17 2011-04-27 Ácidos naftilacéticos CR20110219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11513308P 2008-11-17 2008-11-17
US22218209P 2009-07-01 2009-07-01

Publications (1)

Publication Number Publication Date
CR20110219A true CR20110219A (es) 2011-08-24

Family

ID=41467025

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110219A CR20110219A (es) 2008-11-17 2011-04-27 Ácidos naftilacéticos

Country Status (30)

Country Link
US (1) US8642629B2 (es)
EP (1) EP2346819B1 (es)
JP (1) JP5463365B2 (es)
KR (1) KR101322496B1 (es)
CN (1) CN102216265B (es)
AR (1) AR074352A1 (es)
AU (1) AU2009315712A1 (es)
BR (1) BRPI0921038A2 (es)
CA (1) CA2740863A1 (es)
CO (1) CO6351778A2 (es)
CR (1) CR20110219A (es)
CY (1) CY1114200T1 (es)
DK (1) DK2346819T3 (es)
EC (1) ECSP11011057A (es)
ES (1) ES2408963T3 (es)
HK (1) HK1162461A1 (es)
HR (1) HRP20130613T1 (es)
IL (1) IL212077A0 (es)
MA (1) MA32798B1 (es)
MX (1) MX2011005120A (es)
NZ (1) NZ591914A (es)
PE (1) PE20110703A1 (es)
PL (1) PL2346819T3 (es)
PT (1) PT2346819E (es)
RS (1) RS52809B (es)
RU (1) RU2539185C2 (es)
SG (1) SG171734A1 (es)
TW (1) TWI377197B (es)
WO (1) WO2010055004A1 (es)
ZA (1) ZA201102524B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102099342B (zh) 2008-07-15 2013-07-10 霍夫曼-拉罗奇有限公司 氨基四氢吲唑基乙酸类
US8138208B2 (en) 2008-07-15 2012-03-20 Hoffmann-La Roche Inc. Aminotetrahydroindazoloacetic acids
MX2011005200A (es) 2008-11-17 2011-06-01 Hoffmann La Roche Acidos naftilaceticos.
CN102216273A (zh) * 2008-11-17 2011-10-12 霍夫曼-拉罗奇有限公司 用作crth2拮抗剂或部分激动剂的萘乙酸
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US8470884B2 (en) * 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US8691993B2 (en) * 2011-12-12 2014-04-08 Hoffmann-La Roche Inc. Piperidinyl naphthylacetic acids
CN104011021B (zh) 2011-12-21 2016-08-24 埃科特莱茵药品有限公司 杂环衍生物及其作为前列腺素d2受体调节剂的用途
US9000044B2 (en) * 2012-02-28 2015-04-07 Hoffmann-La Roche Inc. Substituted naphthylacetic acids
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP3656770A3 (en) 2015-04-24 2020-09-09 Syngenta Participations AG Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocycles
EP3565635B1 (en) 2017-01-09 2023-09-27 The Children's Hospital of Philadelphia Methods for diagnosing asthma and compositions for use in targeting the th2 pathway in the treatment of asthma
WO2023165874A1 (en) * 2022-03-01 2023-09-07 Syngenta Crop Protection Ag Pyrimidinyl-oxy-quinoline based herbicidal compounds

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899529A (en) 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
US4443462A (en) 1979-08-06 1984-04-17 Merrell Dow Pharmaceuticals Inc. Antipsychotic 4-(naphthalenyloxy)piperidine derivatives
US4371537A (en) 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
DE3623941A1 (de) 1986-07-16 1988-01-28 Bayer Ag Substituierte amino-5,6,7,8-tetrahydronaphthyl-oxyessigsaeuren, verfahren zu deren herstellung sowie die verwendung als arzneimittel
EP0405602A1 (en) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE4235155A1 (de) 1992-10-19 1994-04-21 Basf Ag Verfahren zur Herstellung von Methylsulfonylbenzoesäuren
JP2562405B2 (ja) 1993-04-06 1996-12-11 花王株式会社 ケラチン繊維処理剤組成物
ATE167181T1 (de) 1993-12-09 1998-06-15 Ono Pharmaceutical Co Naphthylessigsäurederivate als pgez agonisten und antagonisten
GB9516788D0 (en) 1995-08-16 1995-10-18 Agrevo Uk Ltd Fungicides
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
ZA200505523B (en) 2002-12-20 2006-09-27 Amgen Inc Asthma and allergic inflammation modulators
US20070161698A1 (en) 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
BRPI0411673A (pt) 2003-06-20 2006-08-08 Amgen Inc composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
WO2005040114A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds having crth2 antagonist activity
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
US7732618B2 (en) * 2004-09-21 2010-06-08 Wyeth Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof
AU2005289881A1 (en) 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
CA2580621A1 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
KR100889185B1 (ko) 2004-12-21 2009-03-16 에프. 호프만-라 로슈 아게 테트랄린 및 인단 유도체 및 5-ht 길항제로서의 이의용도
ZA200707498B (en) 2005-02-24 2008-11-26 Millennium Pharm Inc PGD2 receptor antagonists for the treatment of inflammatory diseases
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
US7981882B2 (en) 2005-09-01 2011-07-19 Eli Lilly And Company 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
EP2407459A1 (en) * 2005-09-27 2012-01-18 Shionogi & Co., Ltd. Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
WO2007138974A1 (ja) 2006-05-26 2007-12-06 Toyama Chemical Co., Ltd. 新規な複素環化合物またはその塩ならびにその中間体
US20090281154A1 (en) 2006-06-12 2009-11-12 Doherty James B Ophthalmic Compositions for Treating Ocular Hypertension
CA2659055A1 (en) * 2006-07-25 2008-01-31 Sanofi-Aventis 2-phenyl-indoles as prostaglandin d2 receptor antagonists
CL2007003693A1 (es) 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
CN102099342B (zh) 2008-07-15 2013-07-10 霍夫曼-拉罗奇有限公司 氨基四氢吲唑基乙酸类
US8138208B2 (en) 2008-07-15 2012-03-20 Hoffmann-La Roche Inc. Aminotetrahydroindazoloacetic acids
CA2734104A1 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Substituted aminotetralines
CA2735392A1 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Bi-aryl aminotetralines
WO2010018112A2 (en) 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Monoaryl aminotetralines
CN102216273A (zh) 2008-11-17 2011-10-12 霍夫曼-拉罗奇有限公司 用作crth2拮抗剂或部分激动剂的萘乙酸
MX2011005200A (es) 2008-11-17 2011-06-01 Hoffmann La Roche Acidos naftilaceticos.

Also Published As

Publication number Publication date
US8642629B2 (en) 2014-02-04
JP5463365B2 (ja) 2014-04-09
RU2011124150A (ru) 2012-12-27
TWI377197B (en) 2012-11-21
HRP20130613T1 (en) 2013-07-31
WO2010055004A1 (en) 2010-05-20
MA32798B1 (fr) 2011-11-01
CA2740863A1 (en) 2010-05-20
MX2011005120A (es) 2011-05-30
US20100125058A1 (en) 2010-05-20
HK1162461A1 (en) 2012-08-31
BRPI0921038A2 (pt) 2019-09-24
IL212077A0 (en) 2011-06-30
KR20110071121A (ko) 2011-06-28
PE20110703A1 (es) 2011-10-13
ZA201102524B (en) 2014-09-25
NZ591914A (en) 2013-04-26
AU2009315712A1 (en) 2010-05-20
PT2346819E (pt) 2013-05-10
CO6351778A2 (es) 2011-12-20
EP2346819A1 (en) 2011-07-27
PL2346819T3 (pl) 2013-09-30
JP2012508714A (ja) 2012-04-12
CN102216265A (zh) 2011-10-12
RU2539185C2 (ru) 2015-01-20
ECSP11011057A (es) 2011-10-31
DK2346819T3 (da) 2013-05-13
CN102216265B (zh) 2014-04-30
EP2346819B1 (en) 2013-04-10
AR074352A1 (es) 2011-01-12
KR101322496B1 (ko) 2013-10-29
CY1114200T1 (el) 2016-08-31
RS52809B (en) 2013-10-31
SG171734A1 (en) 2011-07-28
TW201022207A (en) 2010-06-16
ES2408963T3 (es) 2013-06-24

Similar Documents

Publication Publication Date Title
CR20110219A (es) Ácidos naftilacéticos
ECSP088082A (es) Derivados de piridazina
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
CO6541606A2 (es) Espiroindolinona- pirrolidinas
ECSP13013074A (es) Nuevos derivados de piridina
CR9703A (es) Derivados de pirazolona
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
UY35259A (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
UY30500A1 (es) Compuestos de azabencimidazolilo
AR077765A1 (es) Inhibidores de los virus flaviviridae
CR20110680A (es) Sulfonamidas heterociclicas, usos y composiciones farmacéuticas de las mismas
CO6741154A2 (es) Compuestos de triazolopiridina
UY31001A1 (es) Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas
UY32977A (es) Novedosos compuestos como inhibidores de la caseina quinasa
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY32605A (es) Agentes antiinflamatorios como compuestos virostáticos
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
NI201100096A (es) Lactamas como inhibidores de beta secretasa.
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
UY30476A1 (es) Noveles compuestos derivados n-sustituidos de la 3-oxoisoindolin-1-carboxamida, sus sales aceptables, composiciones farmaccuticas y aplicaciones.
AR063027A1 (es) Derivados de sulfonamida
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
AR084169A1 (es) Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab